Eversana formed a partnership with thenetworkone, the world’s largest independent marketing and communications agency network.
Britain agreed a partnership with the United States on Thursday to tackle new pandemics by bolstering disease surveillance and genomic sequencing worldwide, on the eve of a G7 leaders’ summit.
The U.S. Food and Drug Administration decided to put together an advisory committee meeting of outside experts to review a New Drug Application (NDA) for FibroGen and partner AstraZeneca’s investigational anemia therapy roxadustat.
Novavax Chief Executive Officer Stanley Erck believes the U.S. Food and Drug Administration could grant Emergency Use Authorization (EUA) for the company’s Covid-19 vaccine by May.
EVERSAN and Havas Health & You announced an exclusive strategic partnership agreement, inclusive of data, analytics and predictive platforms, combined with commercialization services, to offer to health and wellness clients worldwide.
The United States plans a massive testing effort involving more than 100,000 volunteers and a half dozen or so of the most promising vaccine candidates in an effort to deliver a safe and effective one by the end of 2020, scientists leading the program told Reuters.
With a busy week for biotech quarterly and annual reports, here is a look at some of the top stories.
Fingerpaint announced a new partnership with Thrive Global aimed at educating employees through personal health and wellness content and empowering them with the tools they need to improve productivity and manage stress.
The U.S. FDA denied Lexicon Pharmaceuticals Inc.’s appeal against the rejection of the add-on treatment Zynquista for type 1 diabetes, marking the company’s third major setback during 2019.
Parexel will tap into real-world data to connect the biopharmaceutical services provider to data from the company’s clinical trials through a multi-year partnership with Bay Area-based Datavant.